Fosun Pharmaceutical Signs Deal With Neuracle to Buy Alzheimer's Drug Rights

MT Newswires Live

2025/07/29

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through unit Fosun Pharma Industrial, entered into a license agreement with neuroscience research company Neuracle for Alzheimer's drug AR1001, according to a Shanghai bourse on Tuesday.

The Chinese pharmaceutical company will obtain the rights to develop, register, manufacture, and market the drug within the mainland, Hong Kong, and Macau.

Fosun will pay up to 150 million yuan, which includes an upfront payment of 40 million yuan and regulatory milestones of up to 110 million yuan.

The company's Shanghai and Hong Kong shares both rose 2% during late morning trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555891500"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555891500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555891500?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555891500","market":"hk","top_or_hot":-1,"title":"Fosun Pharmaceutical Signs Deal With Neuracle to Buy Alzheimer's Drug Rights","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196), through unit Fosun Pharma Industrial, entered into a license agreement with neuroscience research company Neuracle for Alzheimer's drug AR1001, according to a Shanghai bourse on Tuesday.</p><p>The Chinese pharmaceutical company will obtain the rights to develop, register, manufacture, and market the drug within the mainland, <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a>, and Macau.</p><p>Fosun will pay up to 150 million yuan, which includes an upfront payment of 40 million yuan and regulatory milestones of up to 110 million yuan.</p><p>The company's Shanghai and Hong Kong shares both rose 2% during late morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharmaceutical Signs Deal With Neuracle to Buy Alzheimer's Drug Rights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharmaceutical Signs Deal With Neuracle to Buy Alzheimer's Drug Rights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-29 11:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (SHA:600196, HKG:2196), through unit Fosun Pharma Industrial, entered into a license agreement with neuroscience research company Neuracle for Alzheimer's drug AR1001, according to a Shanghai bourse on Tuesday.</p><p>The Chinese pharmaceutical company will obtain the rights to develop, register, manufacture, and market the drug within the mainland, <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a>, and Macau.</p><p>Fosun will pay up to 150 million yuan, which includes an upfront payment of 40 million yuan and regulatory milestones of up to 110 million yuan.</p><p>The company's Shanghai and Hong Kong shares both rose 2% during late morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00656","symbol_name":"复星国际","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2555891500","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555891500","pubTimestamp":1753760462,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical , through unit Fosun Pharma Industrial, entered into a license agreement with neuroscience research company Neuracle for Alzheimer's drug AR1001, according to a Shanghai bourse on Tuesday.The Chinese pharmaceutical company will obtain the rights to develop, register, manufacture, and market the drug within the mainland, Hong Kong, and Macau.Fosun will pay up to 150 million yuan, which includes an upfront payment of 40 million yuan and regulatory milestones of up to 110 million yuan.The company's Shanghai and Hong Kong shares both rose 2% during late morning trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","00656":"复星国际","BK0188":"融资融券","BK0060":"抗癌","BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","BK0028":"国家队","BK0187":"一线龙头","02196":"复星医药","BK0096":"民营医院","BK0183":"MSCI概念","BK0196":"行业龙头","BK0239":"医药制造"},"translate_title":"复星医药与Neuracle签署协议购买阿尔茨海默病药物权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through unit Fosun Pharma Industrial, entered into a license agreement with neuroscience research company Neuracle for Alzheimer's drug AR1001, according to a Shanghai bourse on Tuesday.The Chinese pharmaceutical company will obtain the rights to develop, register, manufacture, and market the drug within the mainland, Hong Kong, and Macau.Fosun will pay up to 150 million yuan, which includes an upfront payment of 40 million yuan and regulatory milestones of up to 110 million yuan.The company's Shanghai and Hong Kong shares both rose 2% during late morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}